A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1004 participants.

Also called NCT05515367

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,004 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05515367
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
India (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05515367. Allocation not applicable; no masking; primary purpose treatment. Start 2023-04-20 (actual); primary completion 2025-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
Condition
Chronic Kidney Diseases
Condition
Anemia of Chronic Kidney Disease
Intervention (Drug)
Desidustat
Lead sponsor
Zydus Lifesciences Limited (class: industry)

Record details

Record id
cardio:ct-nct05515367
Content hash
65e2ca01da640ec20a2550110c6c49baba6c87ff3ceefa0e9778ea16e548f3a4